

Yi Ba

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3120022/publications.pdf>

Version: 2024-02-01

116
papers

12,459
citations

66343

42
h-index

25787

108
g-index

133
all docs

133
docs citations

133
times ranked

16879
citing authors

#	ARTICLE	IF	CITATIONS
1	Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. <i>Cell Research</i> , 2008, 18, 997-1006.	12.0	4,084
2	Secreted Monocytic miR-150 Enhances Targeted Endothelial Cell Migration. <i>Molecular Cell</i> , 2010, 39, 133-144.	9.7	1,059
3	Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. <i>Journal of Clinical Oncology</i> , 2016, 34, 1448-1454.	1.6	756
4	CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer. <i>Molecular Cancer</i> , 2020, 19, 43.	19.2	543
5	Exosome-delivered EGFR regulates liver microenvironment to promote gastric cancer liver metastasis. <i>Nature Communications</i> , 2017, 8, 15016.	12.8	397
6	A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. <i>European Journal of Cancer</i> , 2011, 47, 784-791.	2.8	385
7	Serum MicroRNA Expression Profile as a Biomarker in the Diagnosis and Prognosis of Pancreatic Cancer. <i>Clinical Chemistry</i> , 2012, 58, 610-618.	3.2	350
8	Exosome-delivered circRNA promotes glycolysis to induce chemoresistance through the miR-122â€PKM2 axis in colorectal cancer. <i>Molecular Oncology</i> , 2020, 14, 539-555.	4.6	327
9	Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 916.	7.4	310
10	Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis. <i>International Journal of Cancer</i> , 2012, 130, 1620-1628.	5.1	251
11	Exosomes Serve as Nanoparticles to Deliver Anti-miR-214 to Reverse Chemoresistance to Cisplatin in Gastric Cancer. <i>Molecular Therapy</i> , 2018, 26, 774-783.	8.2	157
12	miR-143 and miR-145 synergistically regulate ERBB3 to suppress cell proliferation and invasion in breast cancer. <i>Molecular Cancer</i> , 2014, 13, 220.	19.2	145
13	Hypoxia induced exosomal circRNA promotes metastasis of Colorectal Cancer via targeting GEF-H1/RhoA axis. <i>Theranostics</i> , 2020, 10, 8211-8226.	10.0	131
14	Exosomes serve as nanoparticles to suppress tumor growth and angiogenesis in gastric cancer by delivering hepatocyte growth factor siRNA. <i>Cancer Science</i> , 2018, 109, 629-641.	3.9	120
15	Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T 5 colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 660-671.	10.7	107
16	The c-Myc/miR-27b-3p/ATG10 regulatory axis regulates chemoresistance in colorectal cancer. <i>Theranostics</i> , 2020, 10, 1981-1996.	10.0	100
17	Cell-derived microvesicles mediate the delivery of miR-29a/c to suppress angiogenesis in gastric carcinoma. <i>Cancer Letters</i> , 2016, 375, 331-339.	7.2	98
18	Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer. <i>Gastric Cancer</i> , 2016, 19, 234-244.	5.3	90

#	ARTICLE	IF	CITATIONS
19	Exosomal miR-27a Derived from Gastric Cancer Cells Regulates the Transformation of Fibroblasts into Cancer-Associated Fibroblasts. <i>Cellular Physiology and Biochemistry</i> , 2018, 49, 869-883.	1.6	90
20	Exosomal miR-208b related with oxaliplatin resistance promotes Treg expansion in colorectal cancer. <i>Molecular Therapy</i> , 2021, 29, 2723-2736.	8.2	85
21	MicroRNA-181a promotes angiogenesis in colorectal cancer by targeting SRCIN1 to promote the SRC/VEGF signaling pathway. <i>Cell Death and Disease</i> , 2018, 9, 438.	6.3	78
22	Survey and analysis of the nutritional status in hospitalized patients with malignant gastric tumors and its influence on the quality of life. <i>Supportive Care in Cancer</i> , 2020, 28, 373-380.	2.2	78
23	Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study. <i>Cancer Communications</i> , 2021, 41, 1173-1182.	9.2	77
24	Serum miRNA expression profile as a prognostic biomarker of stage II/III colorectal adenocarcinoma. <i>Scientific Reports</i> , 2015, 5, 12921.	3.3	75
25	Exosome-Delivered c-Met siRNA Could Reverse Chemoresistance to Cisplatin in Gastric Cancer. <i>International Journal of Nanomedicine</i> , 2020, Volume 15, 2323-2335.	6.7	67
26	Onco-miR-24 regulates cell growth and apoptosis by targeting BCL2L11 in gastric cancer. <i>Protein and Cell</i> , 2016, 7, 141-151.	11.0	64
27	MiR-193a-3p is an Important Tumour Suppressor in Lung Cancer and Directly Targets KRAS. <i>Cellular Physiology and Biochemistry</i> , 2017, 44, 1311-1324.	1.6	64
28	Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors. <i>Gastric Cancer</i> , 2021, 24, 913-925.	5.3	61
29	iRGD-modified exosomes effectively deliver CPT1A siRNA to colon cancer cells, reversing oxaliplatin resistance by regulating fatty acid oxidation. <i>Molecular Oncology</i> , 2021, 15, 3430-3446.	4.6	57
30	Apigenin enhances the cisplatin cytotoxic effect through p53-modulated apoptosis. <i>Oncology Letters</i> , 2017, 13, 1024-1030.	1.8	56
31	Onco-miR-130 promotes cell proliferation and migration by targeting TGF β 2R2 in gastric cancer. <i>Oncotarget</i> , 2016, 7, 44522-44533.	1.8	55
32	MicroRNA-155 promotes gastric cancer growth and invasion by negatively regulating transforming growth factor β 2 receptor 2. <i>Cancer Science</i> , 2018, 109, 618-628.	3.9	51
33	Nutritional assessment and risk factors associated to malnutrition in patients with esophageal cancer. <i>Current Problems in Cancer</i> , 2021, 45, 100638.	2.0	50
34	MiR-520b/e Regulates Proliferation and Migration by Simultaneously Targeting EGFR in Gastric Cancer. <i>Cellular Physiology and Biochemistry</i> , 2016, 40, 1303-1315.	1.6	45
35	miR-10a inhibits cell proliferation and promotes cell apoptosis by targeting BCL6 in diffuse large B-cell lymphoma. <i>Protein and Cell</i> , 2016, 7, 899-912.	11.0	45
36	Chemotoxicity-induced exosomal lncFERO regulates ferroptosis and stemness in gastric cancer stem cells. <i>Cell Death and Disease</i> , 2021, 12, 1116.	6.3	45

#	ARTICLE	IF	CITATIONS
37	MiR-17-5p regulates cell proliferation and migration by targeting transforming growth factor- β 2 receptor 2 in gastric cancer. <i>Oncotarget</i> , 2016, 7, 33286-33296.	1.8	44
38	The miR-24-Bim pathway promotes tumor growth and angiogenesis in pancreatic carcinoma. <i>Oncotarget</i> , 2015, 6, 43831-43842.	1.8	42
39	Nutritional Risk Assessment by Scored Patient-Generated Subjective Global Assessment Associated with Demographic Characteristics in 23,904 Common Malignant Tumors Patients. <i>Nutrition and Cancer</i> , 2019, 71, 50-60.	2.0	42
40	Cell-derived Exosomes as Promising Carriers for Drug Delivery and Targeted Therapy. <i>Current Cancer Drug Targets</i> , 2018, 18, 347-354.	1.6	41
41	Clinical use of tumor biomarkers in prediction for prognosis and chemotherapeutic effect in esophageal squamous cell carcinoma. <i>BMC Cancer</i> , 2019, 19, 526.	2.6	37
42	Gastric cancer derived exosomes mediate the delivery of circRNA to promote angiogenesis by targeting miR-29a/VEGF axis in endothelial cells. <i>Biochemical and Biophysical Research Communications</i> , 2021, 560, 37-44.	2.1	37
43	Current management of chemotherapy-induced neutropenia in adults: key points and new challenges. <i>Cancer Biology and Medicine</i> , 2020, 17, 896-909.	3.0	35
44	The role of miR-485-5p/NUDT1 axis in gastric cancer. <i>Cancer Cell International</i> , 2017, 17, 92.	4.1	32
45	miR-26a/b Inhibit Tumor Growth and Angiogenesis by Targeting the HGF-VEGF Axis in Gastric Carcinoma. <i>Cellular Physiology and Biochemistry</i> , 2017, 42, 1670-1683.	1.6	30
46	Deregulation of the miR-16-KRAS axis promotes colorectal cancer. <i>Scientific Reports</i> , 2016, 6, 37459.	3.3	28
47	Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial. <i>Chinese Journal of Cancer</i> , 2017, 36, 97.	4.9	28
48	The HSF1/miR-135b-5p axis induces protective autophagy to promote oxaliplatin resistance through the MULK1/ULK1 pathway in colorectal cancer. <i>Oncogene</i> , 2021, 40, 4695-4708.	5.9	28
49	miR-455 inhibits cell proliferation and migration via negative regulation of EGFR in human gastric cancer. <i>Oncology Reports</i> , 2017, 38, 175-182.	2.6	27
50	Classification Tree-Based Machine Learning to Visualize and Validate a Decision Tool for Identifying Malnutrition in Cancer Patients. <i>Journal of Parenteral and Enteral Nutrition</i> , 2021, 45, 1736-1748.	2.6	27
51	The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer. <i>Cancer Communications</i> , 2019, 39, 26.	9.2	26
52	Is hand grip strength a necessary supportive index in the phenotypic criteria of the GLIM-based diagnosis of malnutrition in patients with cancer?. <i>Supportive Care in Cancer</i> , 2021, 29, 4001-4013.	2.2	26
53	lncRNA-encoded pepAP attenuates the pentose phosphate pathway and sensitizes colorectal cancer cells to Oxaliplatin. <i>EMBO Reports</i> , 2022, 23, e53140.	4.5	25
54	Plasma Exosomal miRNA Expression Profile as Oxaliplatin-Based Chemoresistant Biomarkers in Colorectal Adenocarcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 1495.	2.8	24

#	ARTICLE	IF	CITATIONS
55	Integrated analysis of the miRNA, gene and pathway regulatory network in gastric cancer. <i>Oncology Reports</i> , 2016, 35, 1135-1146.	2.6	23
56	Platelet to lymphocyte ratio is a predictive marker of prognosis and therapeutic effect of postoperative chemotherapy in non-metastatic esophageal squamous cell carcinoma. <i>Clinica Chimica Acta</i> , 2018, 479, 160-165.	1.1	23
57	Prognostic nomogram for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy followed by adjuvant chemotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 336-343.	1.3	22
58	miR-221 and miR-222 synergistically regulate hepatocyte growth factor activator inhibitor type 1 to promote cell proliferation and migration in gastric cancer. <i>Tumor Biology</i> , 2017, 39, 101042831770163.	1.8	22
59	miR-370 regulates cell proliferation and migration by targeting EGFR in gastric cancer. <i>Oncology Reports</i> , 2017, 38, 384-392.	2.6	22
60	The patient-generated subjective global assessment is a promising screening tool for cancer cachexia. <i>BMJ Supportive and Palliative Care</i> , 2022, 12, e39-e46.	1.6	22
61	Altered Serum MicroRNA Profile May Serve as an Auxiliary Tool for Discriminating Aggressive Thyroid Carcinoma from Nonaggressive Thyroid Cancer and Benign Thyroid Nodules. <i>Disease Markers</i> , 2019, 2019, 1-11.	1.3	21
62	Effects of miR-138-5p and miR-204-5p on the migration and proliferation of gastric cancer cells by targeting EGFR. <i>Oncology Reports</i> , 2018, 39, 2624-2634.	2.6	19
63	Peroxisome proliferator-activated receptor gamma coactivator-1 alpha acts as a tumor suppressor in hepatocellular carcinoma. <i>Tumor Biology</i> , 2017, 39, 101042831769503.	1.8	17
64	Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-label phase 3 trial. <i>Cancer Communications</i> , 2019, 39, 1-10.	9.2	17
65	Challenges in anticancer drug R&D in China. <i>Lancet Oncology</i> , The, 2019, 20, 183-186.	10.7	16
66	Direct targeting of HGF by miR-16 regulates proliferation and migration in gastric cancer. <i>Tumor Biology</i> , 2016, 37, 15175-15183.	1.8	15
67	Tumor microenvironment interruption: a novel anti-cancer mechanism of Proton-pump inhibitor in gastric cancer by suppressing the release of microRNA-carrying exosomes. <i>American Journal of Cancer Research</i> , 2017, 7, 1913-1925.	1.4	15
68	Expert consensus on maintenance treatment for metastatic colorectal cancer in China. <i>Chinese Journal of Cancer</i> , 2016, 35, 13.	4.9	14
69	Study protocol of the Asian XELIRI Project (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab. <i>Chinese Journal of Cancer</i> , 2016, 35, 102.	4.9	12
70	MiR-181a, a new regulator of TGF- β 2 signaling, can promote cell migration and proliferation in gastric cancer. <i>Investigational New Drugs</i> , 2019, 37, 923-934.	2.6	12
71	Association of frequent amplification of chromosome 11q13 in esophageal squamous cell cancer with clinical benefit to immune check point blockade. <i>Journal of Clinical Oncology</i> , 2019, 37, 4036-4036.	1.6	12
72	The microRNA-124-iGluR2/3 pathway regulates glucagon release from alpha cells. <i>Oncotarget</i> , 2016, 7, 24734-24743.	1.8	12

#	ARTICLE	IF	CITATIONS
73	MGMT in colorectal cancer: a promising component of personalized treatment. <i>Tumor Biology</i> , 2016, 37, 11443-11456.	1.8	11
74	Exosomal miR-155 from gastric cancer induces cancer-associated cachexia by suppressing adipogenesis and promoting brown adipose differentiation via C/EPB1 ² . <i>Cancer Biology and Medicine</i> , 2022, , 1-14.	3.0	11
75	Influence of KDR Genetic Variation on the Efficacy and Safety of Patients with Chemotherapy Refractory Metastatic CRC Who Received Apatinib Treatment. <i>International Journal of General Medicine</i> , 2021, Volume 14, 1041-1055.	1.8	10
76	Recombinant humanized anti-PD-1 monoclonal antibody (JS001) as salvage treatment for advanced esophageal squamous cell carcinoma: Preliminary results of an open-label, multi-cohort, phase Ib/II clinical study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 116-116.	1.6	9
77	Nutritional status and survival of 8247 cancer patients with or without diabetes mellitus results from a prospective cohort study. <i>Cancer Medicine</i> , 2020, 9, 7428-7439.	2.8	8
78	A randomized, double-blind, parallel-group, placebo-controlled, multicenter, phase II clinical study of famitinib in the treatment of advanced metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 513-513.	1.6	8
79	Gemcitabine sensitivity factors, hENT1 and RRM1 as potential prognostic biomarker for advanced biliary tract cancer. <i>International Journal of Clinical and Experimental Medicine</i> , 2014, 7, 5041-9.	1.3	8
80	The relationship between treatment-induced hypertension and efficacy of anlotinib in recurrent or metastatic esophageal squamous cell carcinoma. <i>Cancer Biology and Medicine</i> , 2021, 18, 562-568.	3.0	7
81	Serum microRNAs as Biomarkers for the Noninvasive Early Diagnosis of Biliary Tract Cancer. <i>International Journal of General Medicine</i> , 2021, Volume 14, 1185-1195.	1.8	7
82	Change of SPARC expression after chemotherapy in gastric cancer. <i>Cancer Biology and Medicine</i> , 2015, 12, 33-40.	3.0	7
83	Anticancer drug R&D landscape in China. <i>Journal of Hematology and Oncology</i> , 2020, 13, 51.	17.0	6
84	Prevalence of frailty and prediction of mortality in Chinese cancer patients using a frailty index-based clinical algorithm A multicentre study. <i>Cancer Medicine</i> , 2021, 10, 6207-6217.	2.8	6
85	Identification of miR-135b as a novel regulator of TGF β ² pathway in gastric cancer. <i>Journal of Physiology and Biochemistry</i> , 2020, 76, 549-560.	3.0	5
86	Chinese expert recommendations on management of hepatocellular carcinoma during COVID-19 pandemic: a nationwide multicenter survey. <i>Hpb</i> , 2022, 24, 342-352.	0.3	5
87	Identification of HGF as a novel target of miR-15a/16/195 in gastric cancer. <i>Investigational New Drugs</i> , 2020, 38, 922-933.	2.6	4
88	Gemcitabine plus S-1 versus cetuximab as a third-line therapy in metastatic colorectal cancer: an observational trial. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 21159-65.	1.3	4
89	Recombinant humanized anti-PD-1 monoclonal antibody (JS001) as salvage treatment for advanced gastric adenocarcinoma: Preliminary results of an open-label, multi-cohort, phase Ib/II clinical study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 108-108.	1.6	3
90	Initial dose of apatinib in Chinese patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of stomach or gastroesophageal junction in third- or later-line setting: 500 mg or 850 mg?. <i>Journal of Clinical Oncology</i> , 2018, 36, 35-35.	1.6	3

#	ARTICLE	IF	CITATIONS
91	The incidence and impact of weight loss with cachexia in gastric cancer patients.. Journal of Clinical Oncology, 2015, 33, e20644-e20644.	1.6	3
92	Monosialotetrahexosylganglioside in the treatment of chronic oxaliplatin-induced peripheral neurotoxicity: TJMUCH-GI-001, a randomised controlled trial. EClinicalMedicine, 2021, 41, 101157.	7.1	3
93	Comprehensive Characterization of Transforming Growth Factor Beta Receptor 1 in Stomach Adenocarcinoma Identifies a Prognostic Signature for Predicting Clinical Outcomes and Immune Infiltrates. International Journal of General Medicine, 2022, Volume 15, 3375-3391.	1.8	3
94	Time to raise the bar: Transition rate of phase 1 programs on anticancer drugs. Cancer Cell, 2022, 40, 233-235.	16.8	3
95	The efficacy and safety of anlotinib in refractory colorectal cancer: A double-blinded, placebo controlled, randomized phase III ALTER0703 trial.. Journal of Clinical Oncology, 2021, 39, 65-65.	1.6	2
96	Nutritional status and quality of life in patients with gastric cancer in China.. Journal of Clinical Oncology, 2017, 35, e15508-e15508.	1.6	2
97	The Chinese subgroup from a randomized phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone as second-line treatment of HER2-amplified advanced gastric cancer (AGC) in Asian countries.. Journal of Clinical Oncology, 2013, 31, 4109-4109.	1.6	1
98	Randomized, double-blind, phase III trial of monosialotetrahexosylganglioside versus placebo in GI cancer patients with oxaliplatin induced peripheral neurotoxicity (TJMUCH-GI-001).. Journal of Clinical Oncology, 2018, 36, 10017-10017.	1.6	1
99	Development of non-hematological adverse events in apatinib-treated gastric cancer and their association with clinical outcome: Results from a phase IV study.. Journal of Clinical Oncology, 2018, 36, 4039-4039.	1.6	1
100	Safety of apatinib as third-line or beyond treatment in advanced or metastatic gastric cancer: Results from a multicenter phase IV study (Ahead-G201).. Journal of Clinical Oncology, 2018, 36, e16019-e16019.	1.6	1
101	Safety and efficacy of anti-EGFR monoclonal antibody (SCT200) as second-line therapy in advanced esophageal squamous cell carcinoma. Cancer Biology and Medicine, 2022, 19, 1-1.	3.0	1
102	Influence of chemotherapy on the SPARC expression in gastric cancer.. Journal of Clinical Oncology, 2015, 33, e15087-e15087.	1.6	0
103	The status of PD-L1 expression and TILs among ESCC patients in China and changes after radiation and chemotherapy.. Journal of Clinical Oncology, 2017, 35, e14567-e14567.	1.6	0
104	Effect of region and hospital attribute on outcome of gastric patients treated with apatinib: Data from post-marketing phase IV study.. Journal of Clinical Oncology, 2018, 36, 40-40.	1.6	0
105	Apatinib as third-line or beyond therapy in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of stomach or gastroesophageal junction: An open-label, multicenter, post-marketing phase IV study (Ahead-G201).. Journal of Clinical Oncology, 2018, 36, 103-103.	1.6	0
106	Association of proteinuria, hypertension, and hand-foot-skin reaction with efficacy of apatinib in gastric cancer: Results from the post-marketing study (Ahead-G201).. Journal of Clinical Oncology, 2018, 36, 73-73.	1.6	0
107	Safety and efficacy of apatinib in elderly patients with advanced or metastatic gastric cancer in the post-marketing phase IV study: Subgroup analysis by age (Ahead-G201).. Journal of Clinical Oncology, 2018, 36, 126-126.	1.6	0
108	Prognostic factors for survival in apatinib-treated gastric cancer: Results from a post-marketing phase IV study (Ahead-G201).. Journal of Clinical Oncology, 2018, 36, 19-19.	1.6	0

#	ARTICLE	IF	CITATIONS
109	Comparisons between intestinal and diffuse gastric cancer in response to apatinib: Data from post-marketing phase IV study.. Journal of Clinical Oncology, 2018, 36, 36-36.	1.6	0
110	Effects of apatinib dose interruptions on safety and efficacy in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of stomach or gastroesophageal junction in third- or later-line setting.. Journal of Clinical Oncology, 2018, 36, 142-142.	1.6	0
111	Does hypertension history in patients with advanced gastric cancer has an impact on clinical outcomes following apatinib treatment? A subgroup analysis based on data from Ahead-G201 study.. Journal of Clinical Oncology, 2018, 36, e16022-e16022.	1.6	0
112	BMI differences for clinical outcome in patients with advanced or metastatic gastric cancer treated with apatinib: Data from a post-marketing phase IV study (Ahead-G201).. Journal of Clinical Oncology, 2018, 36, e16027-e16027.	1.6	0
113	Impact of time to progression on first-line therapy on clinical outcomes in advanced gastric cancer treated with apatinib: data from a phase IV study (Ahead-G201).. Journal of Clinical Oncology, 2018, 36, e16021-e16021.	1.6	0
114	Clinical benefit of continuing apatinib beyond progression in advanced or metastatic gastric cancer.. Journal of Clinical Oncology, 2018, 36, e16020-e16020.	1.6	0
115	Effect of ECOG PS on outcome of advanced or metastatic gastric patients treated with apatinib: Analysis from a post-marketing phase IV study.. Journal of Clinical Oncology, 2018, 36, e16026-e16026.	1.6	0
116	Response to apatinib by the number of metastatic organs in patients with advanced or metastatic gastric cancer: Subgroup analysis from a phase IV study (Ahead-G201).. Journal of Clinical Oncology, 2018, 36, e16028-e16028.	1.6	0